Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -7,153.85
- Piotroski Score 2.00
- Grade N/A
- Symbol (PBM)
- Company Psyence Biomedical Ltd. Common Shares
- Price $0.04
- Changes Percentage (-5.96%)
- Change -$0
- Day Low $0.04
- Day High $0.05
- Year High $13.69
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-51,159,048
Income Statement
Quarterly
Annual
Latest News of PBM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
PhRMA shells out to get PBM reform over finish line
PhRMA launches a seven-figure ad blitz to push for a crackdown on pharmaceutical middlemen, focusing on saving benefits for patients. The push is part of a final sprint to pass PBM reforms in the lame...
By POLITICO | 1 week ago -
Rebate Game Played By PBMs And Drug Makers Limits Biosimilar Competition
In the United States, patients are now able to choose lower-priced biosimilars for Humira, an autoimmune disease treatment, due to rebating practices by drug manufacturers and pharmacy benefit manager...
By Forbes | 1 week ago -
PBM vibe check
Legislation targeting pharmacy benefit managers (PBMs) may be included in upcoming legislative packages, pending control of the White House and Congress. Congress debates reforming PBMs to improve dru...
By POLITICO | 1 month ago
